Protocol Ledger

NCT05061823 · Phase III · COMPLETED

Bintrafusp Alfa Program Rollover Study

Interventional Phase III clinical trial protocol NCT05061823 sponsored by EMD Serono / Merck KGaA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-12-01 Enrollment: 22 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05061823
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)22 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05061823
Protocol FieldVerified Registry Value
NCT IdentifierNCT05061823
Consolidated Lead SponsorEMD Serono / Merck KGaA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment22 participants (ACTUAL)
Registered Start Date2021-12-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05061823
Hospital Research SiteLocationSite Profile
Harbin Medical University Cancer HospitalHarbin, ChinaOpen Hospital Dossier ->
Gachon University Gil Medical CenterIncheon, South KoreaOpen Hospital Dossier ->
Asan Medical CenterSeoul, South KoreaOpen Hospital Dossier ->
Seoul National University HospitalSeoul, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI